{
    "id": 30578,
    "fullName": "EGFR M766Q",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR M766Q lies within the protein kinase domain of the Egfr protein (UniProt.org). M766Q has been demonstrated to confer resistance to Egfr inhibitors as a secondary resistance mutation (PMID: 31254668), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 15768,
                    "pubMedId": 31254668,
                    "title": "A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31254668"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "M766Q",
    "createDate": "07/24/2019",
    "updateDate": "01/30/2020",
    "referenceTranscriptCoordinates": {
        "id": 181321,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181305_55181306delATinsCA",
        "cDna": "c.2296_2297delATinsCA",
        "protein": "p.M766Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR M766Q demonstrated resistance to treatment with Gilotrif (afatinib) in culture (PMID: 31254668).",
            "molecularProfile": {
                "id": 32800,
                "profileName": "EGFR M766Q EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15768,
                    "pubMedId": 31254668,
                    "title": "A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31254668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Poziotinib (HM781-36B) resulted in growth inhibition of transformed cells co-expressing EGFR L858R and EGFR M766Q in culture at clinically achievable concentrations (PMID: 31254668).",
            "molecularProfile": {
                "id": 32800,
                "profileName": "EGFR M766Q EGFR L858R"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15768,
                    "pubMedId": 31254668,
                    "title": "A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31254668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR M766Q were sensitive to treatment with Nerlynx (neratinib) in culture (PMID: 31254668).",
            "molecularProfile": {
                "id": 32800,
                "profileName": "EGFR M766Q EGFR L858R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15768,
                    "pubMedId": 31254668,
                    "title": "A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31254668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17830,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma initially harboring EGFR L858R and EGFR T790M was treated with Tagrisso (osimertinib), progressed, and via cell-free DNA testing, was found to have lost EGFR T790M, but acquired EGFR M766Q and preclinical analysis of transformed cells co-expressing L858R and M766Q also demonstrated resistance to Tagrisso (osimertinib) in culture (PMID: 31254668).",
            "molecularProfile": {
                "id": 32800,
                "profileName": "EGFR M766Q EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15768,
                    "pubMedId": 31254668,
                    "title": "A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31254668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR M766Q demonstrated resistance to treatment with Tarceva (erlotinib) in culture (PMID: 31254668).",
            "molecularProfile": {
                "id": 32800,
                "profileName": "EGFR M766Q EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15768,
                    "pubMedId": 31254668,
                    "title": "A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31254668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32799,
            "profileName": "EGFR M766Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32800,
            "profileName": "EGFR M766Q EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 181321,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181305_55181306delATinsCA",
            "cDna": "c.2296_2297delATinsCA",
            "protein": "p.M766Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}